Blood Res.  2014 Sep;49(3):148-153. 10.5045/br.2014.49.3.148.

Serum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor

• Yoo C
• Yoon DH
• Suh C

• KMID: 2172785
• DOI: http://doi.org/10.5045/br.2014.49.3.148

Abstract

Beta-2 microglobulin is synthesized in all nucleated cells and forms the light chain subunit of the major histocompatibility complex class I antigen. Despite its potential role as a convenient and non-invasive prognostic indicator in malignant lymphomas, the influence of serum beta2 microglobulin is currently underestimated, and therapeutic decision making is rarely affected by this marker. Recent studies that included relatively large numbers of patients with specific histologic subtypes showed that serum beta2 microglobulin is a potent prognostic marker in malignant lymphomas. In follicular lymphoma, this effort led to the incorporation of serum beta2 microglobulin as an indicator in a new prognostic model. In this review, we summarize the current evidence supporting the role of serum beta2 microglobulin as a prognostic factor in patients with malignant lymphoma and discuss perspectives for future investigations.

Keyword

Beta-2 microglobulin; Lymphoma; Prognostic factor

MeSH Terms

Decision Making
Humans
Lymphoma*
Lymphoma, Follicular
Major Histocompatibility Complex

Reference

1. Peterson PA, Cunningham BA, Berggard I, Edelman GM. β2-microglobulin-a free immunoglobulin domain. Proc Natl Acad Sci U S A. 1972; 69:1697–1701. PMID: 4558655.

2. Grey HM, Kubo RT, Colon SM, et al. The small subunit of HL-A antigens is beta 2-microglobulin. J Exp Med. 1973; 138:1608–1612. PMID: 4128442.

3. Shi C, Zhu Y, Su Y, Chung LW, Cheng T. Beta2-microglobulin: emerging as a promising cancer therapeutic target. Drug Discov Today. 2009; 14:25–30. PMID: 19056512.

4. Munshi NC, Anderson KC, Bergsagel PL, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood. 2011; 117:4696–4700. PMID: 21292777.

5. Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009; 27:4555–4562. PMID: 19652063.

6. Vassilakopoulos TP, Nadali G, Angelopoulou MK, et al. The prognostic significance of beta(2)-microglobulin in patients with Hodgkin's lymphoma. Haematologica. 2002; 87:701–708. PMID: 12091120.

7. Yoo C, Yoon DH, Jo JC, et al. Prognostic impact of beta-2 microglobulin in patients with extranodal natural killer/T cell lymphoma. Ann Hematol. 2014; 93:995–1000. PMID: 24441948.

8. Federico M, Guglielmi C, Luminari S, et al. Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. Haematologica. 2007; 92:1482–1488. PMID: 18024396.

9. Josson S, Nomura T, Lin JT, et al. β2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells. Cancer Res. 2011; 71:2600–2610. PMID: 21427356.

10. Chen CH, Su CY, Chien CY, et al. Overexpression of beta2-microglobulin is associated with poor survival in patients with oral cavity squamous cell carcinoma and contributes to oral cancer cell migration and invasion. Br J Cancer. 2008; 99:1453–1461. PMID: 18841160.

11. Hagberg H, Killander A, Simonsson B. Serum beta 2-microglobulin in malignant lymphoma. Cancer. 1983; 51:2220–2225. PMID: 6189572.

12. Anderson H, Scarffe JH, Swindell R, Crowther D. Serum beta 2-microglobulin in patients with non-Hodgkin's lymphoma. Eur J Cancer Clin Oncol. 1983; 19:327–331. PMID: 6190656.

13. Hahn JS, Lee S, Chong SY, Min YH, Ko YW. Eight-year experience of malignant lymphoma-survival and prognostic factors. Yonsei Med J. 1997; 38:270–284. PMID: 9409190.

14. Lopez-Guillermo A, Colomo L, Jimenez M, et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol. 2005; 23:2797–2804. PMID: 15728226.

15. Johnson PW, Whelan J, Longhurst S, et al. Beta-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas. Br J Cancer. 1993; 67:792–797. PMID: 8471438.

16. Alici S, Bavbek SE, Kaytan E, Eralp Y, Onat H. Prognostic factors in localized aggressive non-Hodgkin's lymphoma. Am J Clin Oncol. 2003; 26:1–5. PMID: 12576915.

17. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005; 23:7013–7023. PMID: 16145068.

18. Litam P, Swan F, Cabanillas F, et al. Prognostic value of serum beta-2 microglobulin in low-grade lymphoma. Ann Intern Med. 1991; 114:855–860. PMID: 2014946.

19. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004; 104:1258–1265. PMID: 15126323.

20. Press OW, Unger JM, Rimsza LM, et al. A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodinetositumomab. Clin Cancer Res. 2013; 19:6624–6632. PMID: 24130072.

21. Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood. 2000; 95:802–806. PMID: 10648389.

22. Zucca E, Conconi A, Pedrinis E, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood. 2003; 101:2489–2495. PMID: 12456507.

23. Arcaini L, Burcheri S, Rossi A, et al. Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination. Oncologist. 2006; 11:285–291. PMID: 16549813.

24. Yoo C, Yoon DH, Yoon S, et al. Prognostic impact of β2-microglobulin in patients with non-gastric mucosa-associated lymphoid tissue lymphoma. Leuk Lymphoma. 2014; 1–6. PMID: 24913511.

25. Oh SY, Kwon HC, Kim WS, et al. Nongastric marginal zone B-cell lymphoma: a prognostic model from a retrospective multicenter study. Cancer Lett. 2007; 258:90–97. PMID: 17936499.

26. Li ZM, Zhu YJ, Sun J, et al. Serum beta2-microglobin is a predictor of prognosis in patients with upper aerodigestive tract NK/T-cell lymphoma. Ann Hematol. 2012; 91:1265–1270. PMID: 22373550.

27. Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006; 24:612–618. PMID: 16380410.

28. Rodriguez J, Conde E, Gutierrez A, et al. The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica. 2007; 92:1067–1074. PMID: 17640855.

29. Dimopoulos MA, Cabanillas F, Lee JJ, et al. Prognostic role of serum beta 2-microglobulin in Hodgkin's disease. J Clin Oncol. 1993; 11:1108–1111. PMID: 8501496.

30. Chronowski GM, Wilder RB, Tucker SL, et al. An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease. Cancer. 2002; 95:2534–2538. PMID: 12467067.

31. Itoh K, Kinoshita T, Watanabe T, et al. Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan. Int J Hematol. 2010; 91:446–455. PMID: 20198461.

32. Yang J, Zhang X, Wang J, et al. Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. Blood. 2007; 110:3028–3035. PMID: 17644731.

33. Yang J, Cao Y, Hong S, et al. Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma. Clin Cancer Res. 2009; 15:951–959. PMID: 19188166.